BNP Paribas Asset Management
LAB icon

BNP Paribas Asset Management’s Standard BioTools LAB Stock Holding History

BNP Paribas Asset Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.23K Buy
10,037
+3,373
+51% +$4.08K ﹤0.01% 2234
2025
Q4 		$9K Buy
6,664
+1,964
+42% +$2.64K ﹤0.01% 2173
2025
Q3 		$6K Hold
4,700
– – ﹤0.01% 1776
2025
Q2 		$6K Buy
+4,700
New +$5.21K ﹤0.01% 1939

Other funds holding LAB

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

BNP Paribas Asset Management's LAB Position: Q1 2026 in Review

BNP Paribas Asset Management increased its Standard BioTools (LAB) stake by 51% in Q1 2026, buying an estimated $4.08K and bringing the position to 10,037 shares worth $9.23K. The position accounts for ﹤0.01% of the portfolio, ranked #2234.

BNP Paribas Asset Management first reported a position in LAB in Q2 2025 and has held it in 4 quarters since. 155 funds tracked by Wall St. Rank hold LAB as of Q1 2026.

  • BNP Paribas Asset Management held 10,037 shares of Standard BioTools worth $9.23K as of Q1 2026.
  • BNP Paribas Asset Management bought 3,373 Standard BioTools shares in Q1 2026, an estimated $4.08K.
  • Standard BioTools made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q1 2026, its #2234 holding.
  • BNP Paribas Asset Management first reported a position in Standard BioTools in Q2 2025 and has held it in 4 quarters since.
  • 155 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.

Based on BNP Paribas Asset Management's 13F filing for Q1 2026, filed 14 May 2026.